Vested interests are redefining, rebranding and co-opting what is 'biopharmaceutical'. This is not just a matter of semantics—the core identity of the biotech industry and its products is at stake.
References
Rader, R.A. Biopharmaceutical Products in the US and European Markets, 6th ed., 2 vols., (BioPlan Associates, Rockville, MD, 2007). <http://www.biopharma.com/>
Rader, R.A. BioExecutive Intl., March, 60–65 (2005). <http://www.biopharma.com/BioExec_pt1.pdf>
Rader, R.A. BioExecutive Intl., May, 42–49 (2005). <http://www.biopharma.com/BioExec_pt2.pdf>
Walsh, G. & Jefferis, R. Nat. Biotechnol. 24, 1241–1252 (2006).
Akers, M.J. BioProcess Intl. 4, 36–43 (2006).
Webster, C. et al. BioPharm Intl. July, 1 (2003).
Copmann, T. et al. BioPharm Intl. March, 14–24 (2001).
Scott, C. BioProcess Intl. 3, 80 (2005). <http://www.bioprocessintl.com/default.asp?page=article_display&docid=61200511&display=full/>
Walsh, G. Eur. J. Pharm. Sci. 15, 135–138 (2002).
Eby, R.J. et al. The Story of Prevnar (Pharmaceutical Research and Manufacturers Association, Washington, DC, 2008). <http://www.innovation.org/index.cfm/StoriesofInnovation/ InnovatorStories/The_Story_of_Prevnar/>
Ernst & Young . Beyond Borders: Ernst & Young Global Biotechnology Report 2007 (Ernst & Young, New York, 2007).
DeVol, R. et al. Biopharmaceutical Industry Contributions to State and US Economics (Milken Institute, Santa Monica, CA, USA, 2004). <http://www.milkeninstitute.org/pdf/biopharma_report.pdf>
Ernst & Young . Convergence: Ernst & Young's Biotechnology Industry Report, Millennium Edition (Ernst & Young, New York, 2000).
PhRMA. Introduction, 2005 Industry Profile (PhRMA, Washington, DC, 2006). <http://members.phrma.org/publications/publications//2005-03-17.1144.pdf>
PhRMA. Annual Report 2006–2007: Biopharmaceutical Inspiration, (PhRMA, Washington, DC, 2007). <http://www.phrma.org/files/Annual_Report_2006_2007.pdf>
Myshko, D. PharmaVOICE, October, 40–44 (2006).
Frantz, S. Nat. Rev. Drug Discov. 5, 977–979 (2006).
Simons, J. Fortune, 28 February 2006. <http://money.cnn.com/2006/02/27/news/companies/ pluggedin_fortune/index.htm/>
Anonymous. Seeking Alpha. 9 January 2007. <http://seekingalpha.com/article/23696-the-biotech-industry-30-years-of-failure-starting-with-genentech/>
Chase, M. The Wall Street Journal, p. B1 (June 5, 2007). <http://online.wsj.com/public/article/SB118100806142024548-PFa4u2AiKfDHi25uT1jvHmdJZKA_20070612.html?mod=blogs>
Schoemaker, P. & Tomczyk, M.S. BioProcess Intl. 4, 64 (2006).
Rader, R.A. US BIOPHARMACOPEIA Registry of Biopharmaceutical Products (Biotechnology Information Institute, Rockville, MD, USA, 2007). <http://www.biopharmacopeia.com/>
German Association of Research-Based Pharmaceutical Companies (VFA). Biological/Biotechnological Generics Cannot Exist (VFA, Berlin, Germany, July 25, 2006). <http://www.vfa.de/vfa-bio_en/vb_press/vb_positionen_en/biosimilars.html>
Miller, H.I. Trends Biotechnol. 5, 56–59 (2007).
Rader, R.A. BioProcess Intl. 5, 28–39 (March 2007). <http://www.biopharma.com/whatsabiogeneric_pt1.pdf>
Rader, R.A. BioProcess Intl. 5, 20–27 (May 2007). <http://www.biopharma.com/whatsabiogeneric_pt2.pdf>
Katz, K.A. Br. J. Dermatol. 154, 809–812 (2006).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rader, R. (Re)defining biopharmaceutical. Nat Biotechnol 26, 743–751 (2008). https://doi.org/10.1038/nbt0708-743
Issue Date:
DOI: https://doi.org/10.1038/nbt0708-743
- Springer Nature America, Inc.
This article is cited by
-
Histidine-based ionizable cationic surfactants: novel biodegradable agents for hydrophilic macromolecular drug delivery
Drug Delivery and Translational Research (2024)
-
Digital Double Diamond (DiDD) Model Analysis of National Competitiveness Under Digital Transformation: An Application to Healthcare and Pharmaceutical Industries in South Korea and Switzerland
International Journal of Global Business and Competitiveness (2023)
-
Enzyme Engineering Strategies for the Bioenhancement of l-Asparaginase Used as a Biopharmaceutical
BioDrugs (2023)
-
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Journal of Cancer Research and Clinical Oncology (2022)
-
Biosimilars – Chancen und Risiken
Der Internist (2020)